Lexicon Pharma (LXRX): מחיר למכירות

The price-to-sales ratio reflects a rapid launch of sales for current heart failure treatments. Lexicon Pharmaceuticals (LXRX) revenues are based on the sale of patented sotagliflozin for diabetes. However, cash flows remain volatile due to the initial stage of the drugs' market rollout. The value of 21.10 shows the current market valuation of the business relative to its annual turnover.

The P/S ratio measures the market value of a business relative to its annual sales volume, allowing an investor to assess the premium paid per unit of revenue. The current value of 21.10 for the price-to-sales ratio of Lexicon Pharmaceuticals (LXRX) reflects market expectations for the commercialization of Inpefa, where the expansion of insurance coverage in the US is expected to transform current revenues into a sustainable positive cash flow.